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Abstract  
Background: Community pharmacists have a key role to play in the management of allergic rhinitis (AR). Their role is especially 
important because the majority of medications used to treat AR are available for purchase over-the-counter (OTC), allowing patients to 
self-select their own medications and bypass the pharmacists. Patients’ self-selection often results in suboptimal treatment selection, 
undertreated AR and poor clinical outcomes. In order for pharmacists to optimise the care for AR patients in the pharmacy, 
pharmacists need to be able to identify patient cohorts who self-select and are at high risk of mismanagement. 
Objectives: This study aimed to compare the demographics, clinical characteristics and medication selected, between pharmacy 
customers who choose to self-select and those who speak with a pharmacist when purchasing medication for their AR in a community 
pharmacy and identify factors associated with AR patients’ medication(s) self-selection behaviour. 
Methods: A cross-sectional observational study was conducted in a convenience sample of community pharmacies from the Sydney 
metropolitan area. Demographics, pattern of AR symptoms, their impact on quality of life (QOL) and medication(s) selected, were 
collected. Logistic regressions were used to identify factors associated with participants’ medication self-selection behaviour.  
Results: Of the 296 recruited participants, 202 were identified with AR; 67.8% were female, 54.5% were >40 years of age, 64.9% had a 
doctor’s diagnosis of AR, and 69.3% self-selected medication(s). Participants with AR who self-select were 4 times more likely to 
experience moderate-severe wheeze (OR 4.047, 95% CI 1.155-14.188) and almost 0.4 times less likely to experience an impact of AR 
symptoms on their QOL (OR 0.369, 95% CI 0.188-0.727). 
Conclusions: The factors associated with AR patients’ self-selecting medication(s) are the presence of wheeze and the absence of 
impact on their QOL due to AR symptoms. By identifying this cohort of patients, our study highlights an opportunity for pharmacists to 
engage these patients and encourage discussion about their AR and asthma management. 
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INTRODUCTION 
Community pharmacists have a key role in managing 
allergic rhinitis (AR), which is a chronic respiratory 
condition increasing in prevalence.1 It is classically 
characterised by nasal itching, sneezing, anterior/posterior 
rhinorrhoea and nasal congestion, however ocular 
symptoms may present (itchy or watery eyes) as well as 
itchy throat/palate.2 AR currently affects up to 30% of the 
world’s population1,3, with 19% of Australians self-reporting 
AR.4 The socioeconomic burden of AR in Australia has been 
measured to be up to AUD9.4 billion, due to absenteeism 
from the work place, reduce productivity at work and 
treatment cost.1,5  
When left undertreated, AR can impact on the day-to-day 
activities of individuals with the condition1,2 or predispose 
the development or worsening asthma.6-10 Despite having 
up to 90% of patients dually affected by AR and asthma11, 
the majority under-recognise the impact of their AR 
symptoms and its impact on asthma control.12 In fact, a 
high proportion of patients who have uncontrolled asthma, 
experience more severe AR symptoms when compared to 
patients with well controlled asthma.12 The importance of 
optimal treatment for AR increases for patients with both 
AR and asthma, as uncontrolled AR increases asthma-
related risk.13 With optimal AR treatment, patients with 
coexisting AR and asthma have a lower risk for asthma 
related events.9,14  
Early detection and optimal management of AR allows 
patients to minimise the impact of AR on the patient. 
Diagnosis of AR is often a challenge for Health Care 
Professionals (HCPs) because patients underreport their AR 
symptoms and HCPs are not always equipped with 
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resources to make the correct diagnosis of AR. Optimal 
management of AR is further compromised with patients’ 
bypassing the HCPs altogether15,16, with 70% self-selecting 
medication for their AR symptoms.12,16-18 Patients’ self-
selection is suboptimal with only 15% selecting appropriate 
over-the-counter (OTC) medications19 from community 
pharmacies.15,16 The most commonly used medications are 
oral antihistamines, which are not deemed to be the most 
effective medication for moderate-severe AR 
symptoms.16,20 Therefore, despite the high dependence on 
medications, AR sufferers remain undertreated.12,19,21 
With an increasing number of OTC medications being 
available from Australian community pharmacies15 and 
online, the choice of medication becomes more 
complicated. The availability of AR treatments OTC in 
Australia has occurred ahead of other countries, with 
implications for self-medication patterns in rhinitis (and 
other disease states). While pharmacists are ideally placed 
to meet the needs of AR patients, however research has 
suggested that pharmacists are not being consulted by 
patients who visits the pharmacy, they are not taking 
advice from pharmacists for their AR.16,19,22 Pharmacists 
play a crucial role in optimising the management of AR by 
regularly updating patients with the latest knowledge on 
AR management and ensure that they are managing their 
AR with appropriate medications. This is because it has 
been shown that patients lack medical knowledge about 
their condition and treatment, which has led to many 
misconceptions about AR medications.23 Currently, many 
are in search for medications that are more effective for 
their condition20,23,24, and pharmacist can the make most of 
this opportunity to engage with this cohort of patients.  
Clearly, if the management of AR is to improve, it is critical 
that AR patients seek advice from pharmacists when in the 
community pharmacy, in a timely and regular manner. 
Currently, little is understood about why patients choose to 
self-manage, bypassing pharmacists. In order for 
pharmacists to optimise the management of AR, it is 
important to identify patient cohorts who self-select and 
are at high risk of mismanagement. Therefore, this study 
aimed to (i) compare the demographics, clinical 
characteristics and medication(s) selected between 
pharmacy customers who choose to self-select and those 
who interact with a pharmacist when purchasing AR 
medication(s) within the community pharmacy setting and 
to (ii) identify factors associated with AR patients’ 
medication self-selection behaviour. 
 
METHODS 
Study design 
This research took the form of a cross-sectional 
observational study conducted on a sample of pharmacy 
customers purchasing medications to treat AR symptom(s) 
from community pharmacies. The study was approved by 
the University of Sydney Human Research Ethics 
Committee (Ref No. 2015/527).  
Community pharmacies within the Sydney metropolitan 
area who expressed an interest in research or pharmacy 
services were engaged to participate in this research. A 
researcher stood in the pharmacy and approached all 
pharmacy customers who choose to self-select off the shelf 
from the pharmacy and those who spoke to the pharmacist 
in regard to a product request, a symptom request or a 
doctor’s prescription. These pharmacy customers were only 
included in the study if they were purchasing a product for 
AR-related symptoms, i.e. sneezing, rhinorrhoea, nasal 
congestion, itchiness in the nose, ears or palate, 
itchy/watery eyes and wheeze. The sample size was 
calculated to ensure that data were collected from a 
representative sample, based on an estimated proportion 
of 0.5 (50%) of people with AR self-selecting medication in 
a pharmacy.20 A sample of 200 AR participants was 
required.25  
The pharmacy customers were invited to participate if they 
fulfilled the following inclusion criteria: independently self-
selected OTC medication(s) to treat AR-related symptoms 
(i.e. sneezing, rhinorrhoea, nasal congestion, itchiness in 
the nose, ears or palate, itchy/watery eyes and wheeze) or 
interacted with a pharmacist for OTC and/or prescribed 
medication(s) for these symptoms. Pharmacy customers 
who selected medication(s) on behalf of others (parents of 
children less than 18 years old and partners) were also 
included if they were instructed to purchase a particular 
product by others and could complete the data collection 
process and did not violate the following exclusion criteria. 
The exclusion criteria included unable to complete the data 
collection process or expressed disinterest in participation 
(Figure 1). Pharmacy customers, younger than 18 years old 
were not approached, as adolescents are not old enough to 
give their own consent in participating in this study, but 
parents who accompanied them in the pharmacy were 
eligible to participate and answer on their behalf. Also, 
pharmacy customers who were purchasing on behalf of 
their partner were eligible, as in real life, people with AR 
trivialise their condition and people with AR may find it 
more convenient for others to purchase their AR 
medication for them. All participants gave verbal consent 
to participate prior to data collection.  
Participants were classified as having AR, NAR, or ‘other’. 
Classification was based on doctor’s diagnosis self-reported 
by participants or where a previous diagnosis was not 
present, determined by the expert panel of clinicians, 
pharmacists and researchers who applied the criteria for 
the diagnosis of AR according to the ARIA guidelines26, 
which is based on triggers, and symptoms reported. The 
triggers were reported in response to the question: “What 
brings on/makes your symptoms worse?” and “Is there, if 
any, a particular time of the year that these symptom(s) 
occur?”.16 
Variables 
Data were collected using a researcher administered survey 
(online appendix). This included demographic 
characteristics, pattern of AR symptoms, their impact on 
quality of life (QOL), triggering factors and medication(s) 
selected (class of medications and reason for the selection). 
The survey was developed based on the empirical data and 
the framework of the international guidelines – Allergic 
Rhinitis and the Impact on Asthma (ARIA).26 The questions 
in the survey were based on patients’ symptoms and 
medication management of AR and the practicality for 
pharmacists to assess and manage patients with AR in the 
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pharmacy.27 The survey was designed to facilitate quick and 
easy administration and reviewed by specialist clinical 
experts, i.e. a respiratory physician and clinical pharmacists. 
All responses were anonymised, and participants were de-
identified.   
 Bias 
Potential bias in this study may have arisen as a result of: 
convenience sample of pharmacies within a Sydney 
Metropolitan area; the collection of data during high 
allergy seasons; inability to collect data from people who 
have mild AR who are less likely to visit a pharmacy for 
treatment.  
Quantitative variables 
ARIA guidelines classify AR according to patients’ 
symptom(s) severity and impact on QOL experienced.26 
There are four categories; mild or moderate-severe 
intermittent and mild or moderate-severe persistent.26 
Symptoms that occurred less than four days per week or 
less than four weeks per year were classified intermittent, 
and symptoms that occurred more than four days per week 
and more than four weeks per year were classified 
persistent.26  
Participants were asked to report the severity of their 
symptoms in the questionnaire, either none, mild, 
moderate or severe of their presenting symptoms, in 
accordance with Total Symptoms Score (TSS).28 The impact 
of their QOL on participants’ symptoms were also recorded. 
The impacts are related to whether they experienced an 
impact on their daily activities, performance at school or at 
work and/or disturb their sleep. Their symptoms were 
considered moderate-severe if they report their symptoms 
to be moderate or severe in the TSS table or if they report 
the presence of any impact on their QOL. The frequency of 
their symptom occurrence was also recorded in the 
questionnaire, as to whether they experienced symptoms 
less or more than four days per week and/or less or more 
than four weeks per year, 
Statistical analysis 
Data were analysed with SPSS version 24TM (SPSS-IBM, 
Chicago, IL, USA). Descriptive statistics were used, and data 
were compared between participants who self-selected 
and those who interacted with the pharmacist. Categorical 
variables were analysed using the Pearson chi-square test, 
and continuous variables were analysed using the 
independent sample t-test. A series of independent 
variables (participants’ demographics, reported moderate-
severe symptoms, impact of AR symptoms on QOL, 
medications selected) were evaluated to see if it was 
associated with participants’ medication self-selection 
behaviour. These independent variables were statistically 
examined for suitability for inclusion in the multivariate 
logistic regression modelling using univariate logistic 
regression analysis to examine the presence of any binary 
correlations between participants who self-selected and 
each independent variable. Multivariate logistic regression 
analysis was performed on the univariate predictors, with 
p<0.05 used as the threshold for entry into the model, 
which was a value sufficiently significant to ensure 
potential interactions were not disregarded.29 A statistical 
approach to variable selection was chosen as this was an 
exploratory study and no prior assumptions of relationships 
between factors have been established.29 The goodness of 
fit of the logistic regression model was confirmed by the 
Hosmer and Lemeshow test. The final logistic regression 
model was determined with significance levels set at 
p<0.05.
29
 
 
RESULTS  
Data collection occurred in August-September, 2015 and 
April-July, 2016 (Australian Spring and Autumn 
respectively) from 8 community pharmacies, 6 hours/day 
Figure 1. Study Design Overview 
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and 4 days in each pharmacy. Each survey took an average 
of 5 minutes to administer for each participant. A flowchart 
of participants included and excluded are summarised in 
Figure 2. The 37 individuals who did not meet the inclusion 
criteria, were purchasing treatments other than for nasal 
symptoms or were unable to answer questions relating to 
the purchase of the product when purchasing for others.  
 Of the participants with AR, 1.5% (3/202) has mild 
intermittent, 1.5% (3/202) has mild persistent, 43.5% 
(88/202) has moderate-severe intermittent and 53.5% 
(108/202) has moderate-severe persistent. 
Table 1 summarises participants’ demographic 
characteristics. Of the 202 participants identified as having 
AR (Figure 1), 54.5% (110/202) were aged >40 years, 67.8% 
Table 1. Demographic, clinical characteristics and medication class selected of total sample and by those who self-selected 
(n=140) and those who speak with a pharmacist (n=62). 
Survey item 
All participants 
(n=202) 
Self-Selected 
p-value 
Yes (n=140) No (n=62) 
Gender     
Female 137 (67.8%) 100 (71.4%) 37 (59.7%) 0.105 
Male 65 (32.2%) 40 (28.6%) 25 (40.3%)  
Age     
 < 18 years old 15 (7.4%) 12 (8.57%) 4 (4.84%)  
18-39 years old 75 (37.1%) 52 (37.1%) 23 (37.1%) >0.05 
> 40 years old 110 (54.5%) 77 (55.0%) 33 (53.2%)  
HCP diagnosed AR 131 (64.9%) 91 (65.0%) 40 (64.5%) 1.000 
AR symptoms (moderate-severe)     
Sneezing 128 (63.4%) 86 (61.4%) 42 (67.7%) 0.431 
Rhinorrhoea  139 (68.8%) 91 (65.0%) 48 (77.4%) 0.100 
Nasal Congestion 129 (63.9%) 84 (60.0%) 45 (72.6%) 0.112 
Itchy/Watery Eyes 118 (58.4%) 81 (57.9%) 37 (59.7%) 0.877 
Itchy Nose 63 (31.2%) 48 (34.3%) 15 (24.2%) 0.188 
Itchy Ears/Palate 45 (22.3%) 33 (23.6%)  12 (19.4%) 0.585 
Wheeze 27 (13.4%) 24 (17.1%) 3 (4.8%) 0.023 
Frequency of AR symptoms     
Intermittent 91 (45.0%) 62 (44.3%) 29 (46.8%) 0.761 
Persistent 111 (55.0%) 78 (55.7%) 33 (53.2%)  
Seasonal* 124 (61.4%) 84 (60.0%) 40 (64.5%) 0.639 
Identified at least a trigger that affected their AR symptoms 149 (73.8%) 108 (77.1%) 41 (66.1%) 0.119 
AR symptoms impacted on at least one aspect of QOL** 122 (60.4%) 75 (53.6%) 47 (75.8%) 0.003 
Class of medications selected      
Oral Antihistamine 115 (56.9%) 82 (58.6%) 33 (53.2%) 0.539 
Intranasal Antihistamine 2 (0.5%) 2 (1.4%) 0 (0%) 1.000 
Intranasal Corticosteroids 63 (31.2%) 34 (24.3%) 29 (46.8%) 0.003 
Intranasal Decongestant 23 (11.4%) 17 (12.1%) 6 (9.7%) 0.811 
Oral Decongestant 4 (2.0%) 2 (1.4%) 2 (3.2%) 0.589 
Saline 17 (8.4%) 9 (6.4%) 8 (12.9%) 0.168 
* Seasonal – participants reported that their symptoms occurred seasonally or all year round in response to the question “Is 
there, if any, a particular time of the year that these symptom(s) occur?”  
** Aspect of QOL includes Impact on daily activities, performance at school or at work, or sleep disturbance. 
Figure 2. Participants Flowchart 
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(137/202) were female, 35.1% (71/202) had undiagnosed 
AR, and 69.3% (140/202) self-selected medication(s) (Table 
1). There were no significant differences in age groups, 
gender and HCP diagnosis of AR between participants who 
chose to self-select and those who spoke with a pharmacist 
(Table 1).  
Table 1 also summarises participant’s clinical characteristics 
- pattern of symptoms, impact of AR symptoms on QOL, 
triggering factors, and classes of medications selected for 
the symptoms experienced. Moderate-severe rhinorrhoea 
was the most commonly experienced symptom overall, 
followed by nasal congestion and sneezing. Over two-thirds 
(136/202) of participants experienced nasal and ocular 
symptoms in combination with itchiness in the ears/palate, 
with 32.7% (66/202) experiencing nasal symptoms only. 
Oral antihistamines and intranasal corticosteroids were the 
most frequently selected medication classes (Table 1). 
Figure 3 summarises the impact of AR symptoms on QOL by 
participants who self-selected and those who interacted 
with a pharmacist. The majority of the participants in this 
study could identify at least a trigger (Table 1). Those who 
self-selected were more likely be experiencing a wheeze, 
(p=0.023), and less likely to have an impact of AR 
symptoms on QOL (p=0.003) and/or purchase of intranasal 
corticosteroids (p=0.003) (Table 1). 
Following univariate logistic regression analysis, two 
independent variables were significantly correlated with 
medication self-selection; presence of moderate-severe 
wheeze and AR symptoms impacting on at least one aspect 
of QOL (Table 2). There was no correlation between these 
two variables, therefore they were subsequently included 
for analysis in the multivariate logistic regression model. 
Classes of medication selected were not included in the 
model. These variables were statistically significant (chi-
squared=15.546, df=2, p<0.001) (Table 2). Participants who 
self-selected were 4 times more likely to experience 
moderate-severe wheeze (OR 4.047, 95% CI 1.155-14.188) 
and almost 0.4 times less likely to experience AR symptoms 
impacting on their QOL (OR 0.369, 95% CI 0.188-0.727) 
(Table 2). 
 
DISCUSSION 
It is well established that patients commonly and sub-
optimally self-select treatment for their AR, whilst continue 
to live with symptoms which impact on their QOL. This 
study is the first to explore the factors that are associated 
with medication self-selection behaviour of patients with 
AR in a ‘real-life’ setting viz; primary care and community 
pharmacy. Currently, the research question in this study 
has not been addressed to date. Our study revealed that 
the majority of people with AR self-selected OTC 
medication(s) in the community pharmacy to treat AR 
symptoms without speaking to the pharmacist. This study 
also found significant differences between those who self-
selected and those who interacted with the pharmacist. 
The differences were related to the presence of moderate-
severe wheeze and impact of AR symptoms on at least one 
aspect of QOL. Interestingly, symptom severity was not a 
driving factor for participants to interact with the 
pharmacist, although a majority of patients with AR were 
experiencing moderate-severe symptoms. While 
significantly higher proportion of participants who 
interacted with the pharmacist were purchasing intranasal 
corticosteroids compared to those who self-selected 
Table 2. Analysis of factors associated with participants’ medication self-selection behaviour. 
Analysis Predictors B S.E. Wald df Sig. Exp (B) 
95% C.I.for Exp(B) 
Lower Upper 
Univariate 
Moderate-severe wheeze 1.403 0.633 4.917 1 0.027 4.069 1.177 14.067 
Impacted on Quality of Life -0.999 0.342 8.555 1 0.003 0.368 0.189 0.719 
Multivariate 
Moderate-severe wheeze 1.398 0.640 4.772 1 0.029 4.047 1.155 14.188 
Impacted on Quality of Life -0.996 0.346 8.309 1 0.004 0.369 0.188 0.727 
Figure 3. Impact of allergic rhinitis (AR) symptoms on at least one aspect of quality of life (QOL) - daily 
activities, performance and sleep, and each domain individually of total sample (n=202) and by self-selected 
(n=140) and interacted with the pharmacist (n=62) groups. 
Tan R, Cvetkovski B, Kritikos V, Yan K, Price D, Smith P, Bosnic-Anticevich S. Management of allergic rhinitis in the community 
pharmacy: identifying the reasons behind medication self-selection. Pharmacy Practice 2018 Jul-Sep;16(3):1332.  
https://doi.org/10.18549/PharmPract.2018.03.1332 
 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 6 
medication(s), this medication class was not included in the 
logistic regression model as it was an outcome of the 
pharmacist interaction.  
Participants who self-select their own medication were less 
likely to report an impact of their AR symptoms on their 
QOL. In this study, 60% of the patients reported having AR 
symptoms impacting on one or more QOL domains (daily 
activities, performance at work or school, or sleep 
disturbance). There was a disconnection between the QOL 
and the severity of the AR symptoms reported by the 
participants. This is not an uncommon perception, in fact 
this has occurred similarly with other diseases such as 
asthma. Patients with asthma also underperceive the 
severity of their condition.30 This suggests the patients can 
tolerate symptoms but when these symptoms impact on 
their QOL16, it begins to impact on their medication 
management behaviour.  This kind of behaviour has been 
reported in previous literature.20,21,24,31,32 This might also 
reflect the concept of symptoms and patients’ perception. 
From the pharmacist’s perspective, these findings highlight 
that 1) patients who self-select are less likely to experience 
an impact of AR symptoms on their QOL and not speak to 
the pharmacist but pharmacists cannot assume that these 
patients have mild disease and are able to manage it 
without advice; 2) patients’ poor perceptions of their AR 
symptoms are barriers to optimal management of AR16 
and pharmacists should not solely rely on patients’ 
perception to guide optimal treatment. Hence, in 
addressing this problem there are several 
possibilities/recommendations that we propose: 1) 
Pharmacists attempt/aim to approach every patient at least 
initially to assess their condition and follow up about their 
AR on the patients. 2) Pharmacy staff are encouraged to 
prompt patients to speak to the pharmacists before leaving 
the pharmacy. 3) Tools can be available for patients to self-
evaluate their symptoms, such as the visual analogue scale, 
then prompted to speak to the pharmacist when 
appropriate. These tools are available through ARIA. It 
could be placed at the shelving where the AR medications 
are located for patients to evaluate their AR status.  
In trying to determine whether participants had coexisting 
asthma, it was felt that asking the patient whether they 
experienced wheeze was the most non-judgemental and 
appropriate approach in this real-life scenario. In this study, 
the proportion of patients with co-existing wheeze was 
13%, which is at the lower end of the range of the 
published prevalence of asthma amongst AR patients.2 
Participants who self-selected were more likely to be also 
experiencing moderate-severe wheeze in addition to AR. 
While this was both an unexpected and counter-intuitive 
finding, the literature indicates that there are complexities 
associated with asthma patients who are known to 
overestimate their asthma control33 and underestimate the 
seriousness of their asthma.34 Possible explanations for this 
finding could be due to patients’ misinterpretation of the 
term ‘wheeze’ or because patients with asthma consider 
their AR a “minor” condition compared to wheeze. 
However, this study was not able to determine where 
patients place the importance of their wheeze, but it was 
able to clearly suggest that they do not associate their AR 
with their wheeze.  It is important for pharmacists to be 
aware of this finding especially in light of the recent 
“Thunderstorm Asthma” events resulting in serious 
exacerbations and even death.35 Pharmacists should alert 
patients regarding these co-existing conditions, provide 
them with education36,37, and refer them to a general 
practitioner for a diagnosis, as it is critical that these 
patients treat their AR and co-existing conditions optimally. 
Pharmacists should recommend intranasal corticosteroids, 
as literature has shown that this medication does not only 
optimally controls AR symptoms but also reduces asthma 
symptoms.13 
The majority of treatments for AR are available OTC. 
Although this allows for patients to purchase these 
medications OTC, it also provides opportunity for 
mismanagement of AR to occur. Therefore although 65% of 
patients with AR have had a diagnosis, it was possible for 
them to choose incorrect or suboptimal treatment options 
for their conditions. There are three possibilities for this 
situation, 1) patients might be recommended a treatment 
OTC by their doctor, which they may or may not take up or 
2) patients might be prescribed a medication but chose to 
select their own medication OTC or 3) patients with follow 
up scripts from pharmacy. Nonetheless, while the terms 
suboptimally treated, undertreated AR and poor clinical 
outcomes of AR are similar, they are different. Suboptimal 
treatment selection refers to choosing a treatment that is 
not necessarily incorrect however it is not the optimal 
treatment for that patient, under treatment refers to a less 
than optimal amount of what might be an optimal 
treatment and poor clinical outcomes is not related to 
treatment but is describing the clinical 
feature/presentation. 
The strengths of this research are the identification of 
opportunities for pharmacists to intervene in the current 
management of AR in the community pharmacy are 
identified; proper counselling and recommendation of 
medication selection, especially for patients with co-
existing asthma. The limitations of this study are associated 
with the cross-sectional study design, non-randomised 
selection of pharmacies and the limited number of patients 
with mild AR approached. 
 
CONCLUSIONS 
In conclusion, the key factors associated with AR patients’ 
self-selecting medication(s) are the presence of moderate-
severe wheeze and the absence of AR symptoms impacting 
on their QOL. This research highlights the need for 
pharmacists to assist every patient who self-selects OTC 
medications, because this study has demonstrated that 
some patients are likely to be experiencing coexisting 
asthma and maybe underestimating the impact of AR on 
their QOL. Pharmacists should engage their AR patients and 
ensure that a proper diagnosis is obtained, an evaluation 
for coexisting conditions made, impact of the condition on 
QOL assessed and the most appropriate treatment 
recommended. Pharmacists plays the important role in AR 
management and future research should focus on 
providing evidence for the role of the pharmacist in the 
management of AR. Pharmacy staff are encouraged to 
prompt patients to consult pharmacists about their AR 
before leaving the pharmacy. Tools, available through ARIA, 
can also be available for patients, at the shelving where AR 
Tan R, Cvetkovski B, Kritikos V, Yan K, Price D, Smith P, Bosnic-Anticevich S. Management of allergic rhinitis in the community 
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medications are located, for patients to self-evaluate their 
symptoms, such as the visual analogue scale, then 
prompted to speak to the pharmacist when appropriate. 
 
CONFLICT OF INTEREST 
Vicky Kritikos: Received honoraria from AstraZeneca, 
GlaxoSmithKline and Pfizer.  
Kwok Yan: Received honoraria for speaking and consulting 
from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, 
Meda, Mundipharma and Pfizer.  
Peter Smith: Has also been a speaker for Meda, 
GlaxoSmithKline, Novartis, Mundipharma and AstraZeneca.  
David Price: A board membership with Aerocrine, Amgen, 
AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, 
Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; 
consultancy agreements with Almirall, Amgen, 
AstraZeneca, Boehringer Ingelheim, Chiesi, 
GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, 
Pfizer, Teva Pharmaceuticals, and Theravance; grants and 
unrestricted funding for investigator-initiated studies 
(conducted through Observational and Pragmatic Research 
Institute Pte Ltd) from UK National Health Service, British 
Lung Foundation, Aerocrine, AKL Research and 
Development Ltd, AstraZeneca, Boehringer Ingelheim, 
Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, 
Respiratory Effectiveness Group, Takeda, Teva 
Pharmaceuticals, Zentiva, and Theravance; payment for 
lectures/speaking engagements from Almirall, AstraZeneca, 
Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, 
Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, 
Skyepharma, Takeda, and Teva Pharmaceuticals; payment 
for manuscript preparation from Mundipharma and Teva 
Pharmaceuticals; payment for the development of 
educational materials from Novartis and Mundipharma; 
payment for travel/accommodation/meeting expenses 
from Aerocrine, Boehringer Ingelheim, Mundipharma, 
Napp, Novartis, Teva Pharmaceuticals, and AstraZeneca; 
funding for patient enrolment or completion of research 
from Chiesi, Teva Pharmaceuticals, Zentiva, and Novartis; 
stock/stock options from AKL Research and Development 
Ltd, which produces phytopharmaceuticals; owns 74% of 
the social enterprise Optimum Patient Care Ltd, UK, and 
74% of Observational and Pragmatic Research Institute Pte 
Ltd, Singapore; and is peer reviewer for grant committees 
of the Medical Research Council, Efficacy and Mechanism 
Evaluation programme, and Health Technology 
Assessment.  
Sinthia Bosnic-Anticevich: A member of the Teva 
Pharmaceuticals Devices International Key Experts Panel; 
received research support from Research in Real Life; 
payment for lectures/speaking engagements and for 
developing educational presentations from Teva and 
Mundipharma; received Honoria from AstraZeneca, 
Boehringer Ingelheim, GlaxoSmithKline, for her 
contribution to advisory boards/key international expert 
forum. 
 
FUNDING 
This research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sectors. 
 
References 
 
1.  Pawankar, R, Canonica, G, Holgate, S, Loceky, R. World Allergy Organisation (WAO): White book on allergy. Wisconsin: 
World Allergy Organisation. Available at: http://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf  
(accessed August 3, 2018). 
2. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, 
Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta 
I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, et 
al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol. 
2017;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050 
3. Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: 
outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):e7. doi: 10.5415/apallergy.2018.8.e7 
4. AIHW. Australia’s health 2016. Canberra, Australia; 2016.  Contract No.: Cat. no. AUS 199. 
5. Pawankar, R, Canonica, R, Holgate, S, Lockey, R, Blaiss, M. World Allergy Organisation (WAO) White Book on Allergy: 
update 2013. Milwaukee: WAO; 2013. 
6. Oka A, Matsunaga K, Kamei T, Sakamoto Y, Hirano T, Hayata A, Akamatsu K, Kikuchi T, Hiramatsu M, Ichikawa T, 
Nakanishi M, Minakata Y, Yamamoto N. Ongoing allergic rhinitis impairs asthma control by enhancing the lower airway 
inflammation. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):172-8. doi: 10.1016/j.jaip.2013.09.018 
7. Omachi TA, Reddy SR, Chang E, Broder MS, Antonova J, Calhoun W. Allergic status is associated with increased 
number of asthma exacerbations.  Am J Respir Crit Care Med. 2016;193:A4970. 
8. de Groot EP, Nijkamp A, Duiverman EJ, Brand PL. Allergic rhinitis is associated with poor asthma control in children with 
asthma. Thorax. 2012;67(7):582-587. doi: 10.1136/thoraxjnl-2011-201168 
9. Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic 
sinusitis. Am J Rhinol Allergy. 2012;26(3):187-190. doi: 10.2500/ajra.2012.26.3762 
10. Chen J, Britten N. ‘Strong medicine’: an analysis of pharmacist consultations in primary care. Fam Pract. 2000;17(6):480-
483. 
11. Terreehorst I, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA, Hak E, van Wijk RG. Prevalence 
and severity of allergic rhinitis in house dust mite‐allergic patients with bronchial asthma or atopic dermatitis. Clin Exp 
Allergy. 2002;32(8):1160-1165. 
Tan R, Cvetkovski B, Kritikos V, Yan K, Price D, Smith P, Bosnic-Anticevich S. Management of allergic rhinitis in the community 
pharmacy: identifying the reasons behind medication self-selection. Pharmacy Practice 2018 Jul-Sep;16(3):1332.  
https://doi.org/10.18549/PharmPract.2018.03.1332 
 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 8 
12. Bosnic-Anticevich S, Kritikos V, Carter V, Yan KY, Armour C, Ryan D, Price D. Lack of asthma and rhinitis control in 
general practitioner-managed patients prescribed fixed-dose combination therapy in Australia. J Asthma. 2018;55(6):684-
694. doi: 10.1080/02770903.2017.1353611 
13. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of 
asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002;109(1):57-62. doi: 
10.1067/mai.2002.120554 
14. Walker S, Sheikh A. Self reported rhinitis is a significant problem for patients with asthma. Prim Care Respir J. 
2005;14(2):83-87. doi: 10.1016/j.pcrj.2004.10.005 
15. Guirguis LM. Mixed methods evaluation: pharmacists' experiences and beliefs toward an interactive communication 
approach to patient interactions. Patient Educ Couns. 2011;83(3):432-442. doi: 10.1016/j.pec.2011.04.038 
16. Tan R, Cvetkovski B, Kritikos V, Price D, Yan K, Smith P, Bosnic-Anticevich S. Identifying the hidden burden of allergic 
rhinitis (AR) in community pharmacy: a global phenomenon. Asthma Res Pract. 2017;3:8. doi: 10.1186/s40733-017-0036-
z 
17. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire 
survey. Allergy. 2007;62(9):1057-1063. doi: 10.1111/j.1398-9995.2007.01367.x 
18. Canonica GW, Triggiani M, Senna G. 360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, 
pharmacists and patients. Clin Mol Allergy. 2015;13:25. doi: 10.1186/s12948-015-0029-5 
19. Tan R, Cvetkovski B, Kritikos V, Price D, Yan K, Smith P, Bosnic-Anticevich S.The burden of rhinitis and the impact of 
medication management within the community pharmacy setting. J Allergy Clin Immunol Pract. 2018;6(5):1717-1725. doi: 
10.1016/j.jaip.2018.01.028 
20. Williams A, Scadding G. Is reliance on self-medication and pharmacy care adequate for rhinitis patients? Int J Clin Pract. 
2009;63(1):98-104. doi: 10.1111/j.1742-1241.2008.01944.x 
21. Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general 
population. Respir Med. 2006;100(2):354-362. doi: 10.1016/j.rmed.2005.05.012 
22. Lombardi C, Musicco E, Rastrelli F, Bettoncelli G, Passalacqua G, Canonica GW. The patient with rhinitis in the 
pharmacy. A cross-sectional study in real life. Asthma Res Pract. 2015;1:4. doi: 10.1186/s40733-015-0002-6 
23. Cvetkovski B, Kritikos V, Yan K, Bosnic-Anticevich S. Tell me about your hay fever: a qualitative investigation of allergic 
rhinitis management from the perspective of the patient. NPJ Prim Care Respir Med. 2018;28(1):3. doi: 10.1038/s41533-
018-0071-0 
24. Fromer LM, Blaiss MS, Jacob-Nara JA, Long RM, Mannion KM, Lauersen LA. Current Allergic Rhinitis Experiences 
Survey (CARES): Consumers' awareness, attitudes and practices. Allergy Asthma Proc. 2014;35(4):307-315. doi: 
10.2500/aap.2014.35.3766 
25. Hardon A, Hodgkin C. How to investigate the use of medicines by consumers. Geneva Switzerland: World Health 
Organization and University of Amsterdam; 2004. 
26. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, 
van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, 
Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 
2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-
160. doi: 10.1111/j.1398-9995.2007.01620.x 
27. Members of the Workshops. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy - Allergic 
rhinitis and its impact on asthma. Allergy. 2004;59(4):373-387. 
28. Demoly P, Bousquet P, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an 
observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43(8):881-888. doi: 
10.1111/cea.12121 
29. Hosmer DW, Lemeshow S. Introduction to the logistic regression model. In: Applied Logistic Regression, 2nd ed. 
Hoboken, NJ: Wiley; 2005. ISBN: 978-0-471-72214-4. 
30. Price D, David-Wang A, Cho SH, Ho JC, Jeong JW, Liam CK, Lin J, Muttalif AR, Perng DW, Tan TL, Yunus F, Neira G. 
Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy. 2015;8:93-103. doi: 
10.2147/JAA.S82633 
31. Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J, Klimek L, Pitman R, Acaster S, Murray R, Bousquet J. 
The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39. doi: 
10.1186/s13601-015-0083-6 
32. Schafheutle EI, Cantrill JA, Nicolson M, Noyce PR. Insights into the choice between self‐medication and a doctor's 
prescription: a study of hay fever sufferers. Int J Pharm Pract. 1996;4(3):156-161. 
33. Bereznicki BJ, Chapman MP, Bereznicki LR. Factors associated with overestimation of asthma control: A cross-sectional 
study in Australia. J Asthma. 2017;54(4):439-446. doi: 10.1080/02770903.2016.1226899 
34. Price D, Fletcher M, Van Der Molen T. Asthma control and management in 8,000 European patients: the REcognise 
Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. doi: 
10.1038/npjpcrm.2014.9 
35. D'Amato G, Vitale C, D'Amato M, Cecchi L, Liccardi G, Molino A, Vatrella A, Sanduzzi A, Maesano C, Annesi-Maesano I. 
Thunderstorm related asthma: what happens and why. Clin Exp Allergy. 2016;46(3):390-396. doi: 10.1111/cea.12709 
36. Lourenço O, Calado S, Sá-Sousa A, Fonseca J. Evaluation of allergic rhinitis and asthma control in a Portuguese 
community pharmacy setting. J Manag Care Spec Pharm. 2014;20(5):513-522. doi: 10.18553/jmcp.2014.20.5.513 
37. Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am. 
2016;36(2):235-248. doi: 10.1016/j.iac.2015.12.002 
 
